SOMATULINE Autogel 90 mg IN DUMPING SYNDROME

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

December 2, 2013

Study Completion Date

December 2, 2013

Conditions
Dumping Syndrome
Interventions
DRUG

Lanreotide 90 mg slow release formulation

Lanreotide 90 mg slow release formulation is injected deep subcutaneously, every 4 weeks, three times and compared to placebo

DRUG

Placebo

Placebo for somatuline slow release 90 mg

Trial Locations (3)

3000

University Hospitals Leuven, Leuven

3600

ZOL Genk, Genk

8310

AZ St. Lucas, Brugges

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

Universitaire Ziekenhuizen KU Leuven

OTHER